Monitor future 8-K filings for actual equity grant details under the new plan. The approval is routine and does not change the company's near-term outlook.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 30 $541.83entry
- T+1 · 5mo ago +0.98%α +1.12% · $547.15
- T+5 · 4mo ago +1.00%α +0.40% · $547.25
- T+20 · 4mo ago −2.56%α −1.54% · $527.94
- T+60 · 8w ago −9.67%α −12.49% · $489.42
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
United Therapeutics shareholders approved the 2026 Stock Incentive Plan at the annual meeting, adding 1,500,000 new shares plus the remaining 2,413,730 shares from the prior plan to the equity compensation reserve. All 12 director nominees were elected, and the advisory say-on-pay resolution passed with 97% support. This is a routine governance filing with no material financial impact.
Key Facts
- Shareholders approved the 2026 Stock Incentive Plan with 25,872,075 votes for and 10,070,290 against (72% of votes cast in favor).
- The plan adds 1,500,000 new shares plus 2,413,730 shares remaining from the prior plan, with potential additional shares from forfeited awards.
- All 12 director nominees were elected with strong support (lowest 'for' vote was 32,342,983 for Christopher Causey).
- Advisory vote on executive compensation passed with 35,152,059 votes for (97% of votes cast).
- Ernst & Young LLP was ratified as independent auditor for 2026 with 35,753,887 votes for.
Financial Impact
No immediate financial impact; the plan authorizes future equity grants but no specific grants were made in this filing.
Risk Factors
- Potential future dilution from equity grants under the new plan, though the 1,500,000 new shares represent approximately 3% of outstanding shares.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-078865 |
| Document: tm2619258d1_8k.htm | 0001104659-26-078865 |
| Document: 0001104659-26-078865-index-headers.html | 0001104659-26-078865 |
| Document: 0001104659-26-078865-index.html | 0001104659-26-078865 |
| Document: 0001104659-26-078865.txt | 0001104659-26-078865 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers